{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1600","upperLimit":"111000","value":"20000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Serum levels were determined for 38 circulating proteins. Values showing statistically significant, ≥2-fold difference compared with baseline are reported here. Statistically significant, \\>=2-fold baseline difference was only seen for MMP-3 (Matrix metalloproteinase-3) at Induction Cycle 1/Day 3.","dispersionType":"Full Range","groups":[{"description":"Included all participants who received oral glasdegib in combination with cytarabine/daunorubicin in phase 1B portion.","id":"OG000","title":"Phase 1B: Glasdegib + Cytarabine/Daunorubicin"}],"paramType":"MEDIAN","populationDescription":"Pharmacodynamic (PD) analysis set: all enrolled participants in the Phase 1B portion who received at least 1 dose of glasdegib, and had at least 1 PD parameter from the corresponding assay sample with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Induction Cycle 1/Day 3, 1 Hour Post dose","title":"Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 3","type":"SECONDARY","unitOfMeasure":"pg/mL"}